It also follows that IL-8 and MIF could represent alternative therapeutic targets in IBD, RA, and SLE which, if precisely targeted, may avoid some of the adverse effects associated with long-term corticosteroid therapy [50]. Here, MIF is linked to inflammatory bowel disease.